tbuckley/cabot-search huggingface dataset:
Abstract 3695: Efficacy of gemcitabine combined with hyperthermia therapy in the treatment of unresectable pancreatic cancer: Phase II study
Authors: Reiko Tsuchiya, Takeshi Ishikawa, Manabu Okajima, Tatsuzo Matsuyama, Naohisa Yoshida, Kazuhiro Katada, Kazuhiro Kamada, Naoyuki Sakamoto, Kazuhiko Uchiyama, Osamu Handa, Tomohisa Takagi, Hiroaki Ysuda, Jyunichi Sakagami, Hideyuki Konishi, Nobuaki Yagi, Satoshi Kokura, Yuji Naito
Journal: Cancer Research (2012)

Abstract [Background] Pancreatic cancer is an aggressive malignant tumor. Gemcitabine is the standard first line therapy for pancreatic cancer. Several gemcitabine based chemotherapy combinations were studied for the treatment of pancreatic cancer, but these combination therapies showed no major success over single agent gemcitabine in the treatment of pancreatic cancer. Hyperthermia has been shown to increase the cytotoxic effects of some anticancer agents by facilitating drug penetration into tissue, and Gemcitabine has recently been shown to be a potent hyperthermic sensitizer in preclinical studies. We conducted a phase II study to determine the availability of combination therapy with gemcitabine and hyperthermia in the treatment of unresectable pancreatic cancer. [Methods] Patients who participated in the study had advanced pancreatic cancer and their performance status score ware 0-2. The primary end point was one-year survival rate. And the secondary end points were safety and response rate. We set the expectation one-year survival rate to 30% Gemcitabine (1000mg/m2) was given weekly for 3 weeks (day 1,8,15) in four-week cycles, and hyperthermia (40min/once) weekly. This schedule was repeated until disease progression. [Result] From November 2008 to November 2009,18 patients were enrolled in this study. Median patient age was 64 years old(range 47-78), male/female:10/8 All patient died until September 2011, and the one year survival rate is 33.3%, exceeded the expected rate. Disease control rates (CR+PR+SD) were 61.1% (PR/SD/PD=2/9/7) Median survival times were 6 months. Adverse events (Grade3/4) were neutropenia (16.7%), anemia (16.7%), anorexia (5.6%), gastrointestinal bleeding (5.6%). [Conclusion] Combination therapy with gemcitabine and hyperthermia is both a safe and effective treatment in patients with advanced unresectable pancreatic cancer. To clarify the effects of sequential combination of hyperthermia and Gemcitabine as compared with Gemcitabine monotherapy, further studies should be performed, particularly prospective randomized trials. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3695. doi:1538-7445.AM2012-3695
Unilateral Breast Uptake on Radionuclide Ventriculography
Authors: Matthieu Pelletier-Galarneau, Oyebola O. Sogbein, Xuan H. Pham, Lionel S. Zuckier
Journal: Clinical Nuclear Medicine (2014)

Gated equilibrium radionuclide ventriculography is frequently used to measure the left ventricular ejection fraction. We report a case of unilateral breast activity resulting in significant underestimation of the left ventricular ejection fraction, which mimicked a left ventricular aneurysm, pseudoaneurysm, or an intrathoracic vascular mass. Unilateral breast uptake, in the absence of gastric activity, was presumed because of increased blood pool in the lactating breast, a finding not previously reported in the literature. This case is also presented to emphasize the importance of localizing abnormalities based on a review of tomographic images or images taken in at least 2 orthogonal projections.
Case 21-2003
Authors: Michael Ronthal, R. Gilberto Gonzalez, R. Neal Smith, Matthew P. Frosch
Journal: New England Journal of Medicine (2003)

Presentation of CaseA 72-year-old, right-handed man was admitted to the hospital because of recurrent neurologic symptoms.The patient had been well until 10 days earlier, when he briefly had numbness of the right side of the mouth and tongue. That evening, he had slurred speech and a hyponasal quality in his speech for 30 minutes, and vertical diplopia later developed but soon cleared. The next morning, there was a brief recurrence of the vertical diplopia, followed by vertigo. Later that morning, transient diplopia again recurred, and the patient came to this hospital and was admitted.The patient had undergone . . .
Abstract 2956: Prognostic value of PCNA expression in salivary gland cancer in consideration of different histological subtypes
Authors: Markus Stenner, Ariane Demgensky, Christoph Molls, Aline Hardt, Jens P. Klussmann
Journal: Cancer Research (2011)

Abstract Background: The expression of the cell proliferation-related marker Proliferating Cell Nuclear Antigen (PCNA) has shown to be a significant prognostic indicator in various human cancers. Its role in malignant tumors of the major salivary glands remains unclear. Methods: We analysed the expression of PCNA in 159 patients with parotid gland cancer (12 different histological subtypes) by means of immunohistochemistry. Patients were divided into two groups due to the median PCNA expression level. The experimental findings were correlated with clinicopathological and survival parameters. The mean follow-up time was 56.6 months. Results: Cytoplasmic expression of PCNA was found in 89% of cases. A high cytoplasmic expression of PCNA was found in 47% of the examined tumors. High cytoplasmic PCNA expression was an independent prognostic indicator for a significant poorer 5-year disease-free survival rate (50.6% versus 73.8%, p=0.036) as well as overall survival rate (57.0% versus 78.8%, p=0.006). Conclusion: The correlation between cytoplasmic PCNA expression and survival probabilities of salivary gland cancer might make this an effective tool in patient follow-up, prognosis and therapy in future. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2956. doi:10.1158/1538-7445.AM2011-2956
Genes, Yew Trees, Lasagna, and More: Top 1990 Cancer Stories
Authors: K. Smigel
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Genes, Yew Trees, Lasagna, and More: Top 1990 Cancer Stories Get access Kara Smigel Kara Smigel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 1, 2 January 1991, Pages 10–12, https://doi.org/10.1093/jnci/83.1.10 Published: 02 January 1991
Narrow band imaging of adenocarcinoma arising from ectopic gastric mucosa in the upper esophagus
Authors: K. Nonaka, M. Watanabe, H. Yuruki, A Okuda, K. Sakurai, K. Iyama, Y. Sasaki
Journal: Endoscopy (2013)

Adenocarcinomas arise rarely in the cervical and upper esophagus [1]. Among these, esophageal adenocarcinomas arising from ectopic gastric mucosa are extremely rare [2] [3] [4]. We report the first patient to undergo magnifying endoscopy with narrow band imaging (NBI) and endoscopic submucosal dissection (ESD) for an esophageal adenocarcinoma arising from ectopic gastric mucosa in the upper thoracic esophagus.
Abstract 357: Induction of galectin-1 decreases radiosensitivity of patient-generated primary cell lines through AKT activation
Authors: Mike Siedow, Arnab Chakravarti, Tim Lautenschlaeger
Journal: Cancer Research (2010)

Abstract Glioblastoma, grade IV malignant glioma based on the WHO classification, is one of the most common brain tumors found in adults and has an average survival time of twelve to sixteen months. The dismal prognosis associated with these tumors is largely due to their ability to grow and proliferate despite radiotherapy, which along with resection and Temozolomide is the current standard of care. A better understanding of the molecular mechanisms that define this malignant phenotype may result in new therapeutic targets and lead to improvements in how patients are treated. Galectin 1(GAL1), a beta-galactosidase binding protein, is strongly expressed in a variety of human cancers and has been shown to be upregulated by irradiation. In this study, we investigated the role of GAL1 upregulation following irradiation in a variety of patient-generated primary cell lines and its role in cell survival. Patient-generated primary cell lines were characterized using a variety of assays such as MTS, Annexin V, and cell viability. Western Blot analysis was performed probing for a variety of proteins implicated in proliferation, motility, and apoptosis. Radiation sensitivities were established by performing Clonogenic Survival Assays comparing the surviving fraction of patient-derived cell lines with established stable cell lines. 6 Gy irradiation upregulated Galectin 1 protein levels in the majority of primary cells used in our study. Furthermore, cell lines which Gal1was upregulated also displayed induction of Phospho-AKT and were significantly less sensitive to irradiation. The combination of GAL1 upregulation and Phosho-AKT induction following irradiation was associated with a significant decrease in the radiosensitization of the patient-derived primary cell lines used in our study. Interestingly, the patient-derived cell lines which showed no upregulation of GAL1 or Phospho-AKT induction displayed markedly increased sensitivity to radiation elucidating an interesting association between GAL1, Phospho-AKT, and radiation-sensitivity. The underlying mechanism by which GAL1 may medicate radioresistence seems to be through AKT activation, a well-documented protein involved in cell survival. Additional studies are ongoing to validate Galectin 1 as a target for radiation sensitization. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 357.
Mammographic density and breast cancer risk in Chinese women.
Authors: J Gao, W Zhao, R Lian, X Liang
Journal: Cancer Research (2009)

Abstract Abstract #4081 Introduction: Mammographic density has been widely accepted as an important breast cancer risk factor. Women with high mammographic density are believed to have an elevated risk of breast cancer. However, no such association has been shown in native Chinese women so far. We carried out a matched case-control study to evaluate the relationship between mammographic density and the risk of breast cancer among Chinese women in a province of Northern China.&amp;#x2028; Method: Cases included 220 women histologically confirmed with breast cancer at a cancer hospital in Northern China between 2005 and 2007. Each case was matched to a control subject with the similar age (within two years old) who attended the same hospital in the same year and diagnosed as benign breast disease or normal breast. Mammograms were the films used for diagnosis. Breast density was evaluated according to Wolf parenchyma patterns through digitalized normal Medio-Lateral Oblique (MLO) mammography view without knowledge of diagnosis. Risk factor information was obtained from archival database of patient-provided information.&amp;#x2028; Results: Compared to women with low-risk (N1 and P1) mammographic parenchymal patterns, those with high-risk patterns (P2 and DY) had an increased risk of breast cancer (odds ratio = 1.9; 95% confidence interval: 1.1 - 3.2) after adjustment for body mass index, age at menarche, and number of full-term pregnancies. There was no statistically significant difference in this association between premenopausal and postmenopausal women.&amp;#x2028; Conclusion: These results indicate that high mammographic density is associated with the risk of breast cancer in native Chinese women. A larger scale study with the validated computer-assisted mammographic density measurement method is being carried out to further confirm this association. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4081.
THU0527 Functional Limitations in Patients with Chronic Gout Compared to Matched Patients with Rheumatoid Arthritis as Measured with HAQ-DI and PF-10
Authors: E. Taal, M. A. Oude Voshaar, P. M. ten Klooster, H. E. Vonkeman, M. A. van de Laar
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To compare functional limitations in patients with chronic gout and matched patients with rheumatoid arthritis (RA) as measured with the HAQ-DI and PF-10. <h3>Methods</h3> Consecutive patients with crystal deposition proven gout (n=102) or with RA (n=619) visiting the outpatient rheumatology clinic of the hospital in Enschede, the Netherlands completed the HAQ-DI and PF-10. Gout patients were matched to patients with RA on sex, age (± 5 years) and disease duration (±5 years). Ninety-three patients with gout could be successfully matched to 93 patients with RA. The HAQ-DI contains 20 items measuring physical disabilities over the past week in eight categories of daily living. Items are scored on a 4-point rating scale from 0 (without any difficulty) to 3 (unable to do). A total score is calculated by averaging the highest score in each category if at least six categories are completed. The PF-10 is the physical functioning scale of the multidimensional SF-36v2. It measures current limitations in a variety of physical activities using 10 items. Items are scored from 1 (yes, limited a lot) to 3 (no, not limited at all). Scores on the PF-10 items are summed and linearly transformed to range between 0 and 100, with higher scores indicating better functioning. <h3>Results</h3> In both disease groups mean age was 59 (± 12) years, mean disease duration was 7 (±9) years and 86% of patients were male. Median PF-10 scores did not significantly differ between patients with gout or with RA and ceiling effects (no limitations) were similar (6.7% versus 6.5%) (see table). However, patients with RA had significantly worse HAQ-DI total scores than patients with gout, and ceiling effects were significantly lower in RA than in gout. Analysis of HAQ-DI category scores showed that gout patients had less limitations in activities that involve the upper extremities such as Dressing, Eating, Hygiene and Grip than RA patients, while scores for activities mostly involving the lower extremities were similar. <h3>Image/graph:</h3> <h3>Conclusions</h3> Gout patients have less functional limitations than RA patients according to HAQ-DI total scores, while according to PF-10 scores gout patients and RA patients do not significantly differ in functional limitations. HAQ-DI seems to underestimate the functional limitations of gout patients compared to RA patients because of the inclusion of activities involving upper extremities, which may be less relevant for patients with gout. On the other hand PF-10 seems to underestimate the functional limitation of patients with RA because of the emphasis on activities involving lower extremities. <h3>Disclosure of Interest</h3> None Declared
MIDAZOLAM EN LA SEDACIÓN MODERADA CON PROPOFOL PARA LA COLONOSCOPIA: UN ENSAYO CLÍNICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO
Authors: J Molina Infante, G Vinagre Rodríguez, M Hernández Alonso, B Pérez Gallardo, C Dueñas Sadornil, JM Mateos Rodríguez, M Fernández Bermejo
Journal: Endoscopy (2010)

Antecedentes: La capacidad para inducir sedación profunda limita el uso generalizado del propofol. Objetivos: Evaluar el impacto de la inducción con midazolam (M) en la sedación moderada con propofol durante la colonoscopia en una unidad de endoscopia sin sala de reanimación.
PubMed is urged to include competing interest information in abstracts
Authors: Michael McCarthy
Journal: BMJ (2016)

Five United States senators and a group of scientists and physicians have called on the US National Library of Medicine to require journals to include information about authors’ competing interests in the abstracts of articles submitted to PubMed, the library’s online database of biomedical literature.

The database is a major resource for both lay and professional researchers: it provides free online access to more than 25 million citations from journals and books in the fields of biomedicine and health, including life sciences, behavioral …
A COMPARATIVE STUDY OF CARDI-O-FIX SEPTAL OCCLUDER VERSUS AMPLATZER SEPTAL OCCLUDER IN PERCUTANEOUS CLOSURE OF SECUNDUM ATRIAL SEPTAL DEFECTS
Authors: Mehmet Kaya, Turkay Saritas, Yat Yin Lam, Ahmet Celebi
Journal: Journal of the American College of Cardiology (2013)
BM-29 * NUMBER OF BRAIN METASTASES INFLUENCES SURVIVAL FOLLOWING GAMMA KNIFE RADIOSURGERY
Authors: S. Saad, T. J. C. Wang, A. Jani, Y. H. Qureshi, A. Yaeh, T. Nanda, T. Rozenblat, M. B. Sisti, J. N. Bruce, G. M. McKhann, A. B. Lassman, S. R. Isaacson
Journal: Neuro-Oncology (2014)

We sought to investigate the oncologic outcome of brain metastases (BM) patients treated with Gamma Knife Radiosurgery (GKRS) based on the number of metastases. The Columbia University Medical Center database was queried for patients treated with GKRS from 1998 to 2013. There were 526 patients (233 men) with median age 62 years. Patients were divided into two groups; group 1 included patients with 1-3 BM and group 2 included patients with 4-12 BM. Primary cancers included 257 (48.7%) lung, 102 (19.3%) breast, 62 (11.7%) melanoma, 40 (7.6%) renal cell, 29 (5.5%) gastrointestinal, and 36 (7.2%) other. 206 (39.2%) patients received GKRS alone, 109 (20.7%) GKRS plus whole brain radiotherapy (WBRT), 109 (20.7%) GKRS plus neurosurgical resection (NSG), and 102 (19.4%) all three modalities. 423 (80.4%) patients had 1-3 BMs and 103 (19.6%) had 4-12 BMs. Median overall survival (mOS) determined by Kaplan-Meier was 16.62 months. mOS for patients with 1-3 BMs and 4-12 BMs was 18.4 months and 13.0 months, respectively (log-rank p = 0.021). mOS for patients with 1-3 BM treated with GKRS alone, GKRS plus WBRT, GKRS plus NSG and all three modalities was 9.5, 20.6, 27.8, and 25.4 months respectively (p < 0.001), mOS for patients with 4-12 BM treated with GKRS alone, GKRS plus WBRT, GKRS plus NSG and all three modalities was 7.4, 15.2, 6.3, 16.4 respectively (p < 0.001). Age at time of treatment, KPS, primary disease status and treatment modalities were significant predictors of survival on univariate and multivariate analysis (p < 0.05). Gender, RPA class, GPA score were statistically significant only on univariate analysis (p < 0.05). Results indicate a significant difference in the overall survival between the two groups, also NGS was more effective in patients with 3 or less lesions, whereas WBRT was more effective in patients with greater number of lesions.
Abstract 2920: Effect of nitric oxide on invasiveness and metabolism of cancer cells.
Authors: Christine A. Caneba, Juan Marini, Deepak Nagrath
Journal: Cancer Research (2013)

Abstract Nitric oxide synthase (NOS) expression has been shown to be upregulated in cancer cells compared to normal cells. The resulting increased nitric oxide (NO) production changes the metastatic ability of cancer cells. The link between NOS expression, NO production, apoptosis, and drug resistance in ovarian cancer is beginning to be studied. However, the effect of NO on metabolism and invasiveness of ovarian cancer cells is not known. Here, using gas chromatography - mass spectroscopy based isotope analysis we show that highly-invasive ovarian cancer cells convert arginine to citrulline via the nitric oxide pathway as opposed to less-invasive ovarian cancer cells. We hypothesize that NO is important for the proliferation, migration, invasion, and drug resistance in highly-invasive ovarian cancer cells as opposed to less-invasive ovarian cancer cells, and that these changes in metastatic behavior are linked to changes in metabolism. We show that L-NG-Nitroarginine Methyl Ester (L-NAME), an inhibitor of NOS, decreases NO production and thus decreases proliferation, migration, and invasion of ovarian cancer cells, as well as decreases drug resistance. Using metabolic assays, we show that NO affects the glucose consumption, lactate secretion, and pyruvate uptake, and provides us with clues regarding the effect of NO on glycolytic activity of highly-invasive and less-invasive ovarian cancer cells. Lastly, we show that NO affects oxygen consumption rate in these cells, and thus oxidative phosphorylation. Our findings are the first to link NO production and invasiveness with metabolism in ovarian cancer cells. Citation Format: Christine A. Caneba, Juan Marini, Deepak Nagrath. Effect of nitric oxide on invasiveness and metabolism of cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2920. doi:10.1158/1538-7445.AM2013-2920
THU0516 Underweight and Obese Rheumatoid Arthritis Patients have Worse Physical Function and Lower Health-Related Quality of Life Than Normal and Overweight Patients
Authors: C. Austad, T. K. Kvien, T. Uhlig
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Patients with long standing rheumatoid arthritis (RA) are more prone to develop rheumatoid cachexia which is associated with increased morbidity and premature mortality. Over the last decades improved RA treatment has resulted in reduced inflammation, and patients report better physical function. Being underweight or obese may be associated with worse physical function and higher disease activity in established RA, but the underlying mechanisms are unclear. <h3>Objectives</h3> To examine whether patient reported outcomes (PRO) differ between underweight (UW), normal weight (NW) overweight (OW) and obese (OB) RA patients during 5 cross-sectional examination points over 15 years. <h3>Methods</h3> Mailed surveys were sent to all patients in the Oslo RA registry (ORAR) in 1994/1996/2001/ 2004/2009. ORAR is representative for RA patients in Oslo aged 20-79 years. Response rates were 931(74.5%)/ 1025(74.5%)/ 893(58.5)/ 914(62.9%)/ 986(59.7%) respectively, with a 3:1 female: male ratio. The questionnaires included the modified health assessment questionnaire (MHAQ), SF-36 (also used to compute SF6D), visual analogue scales for pain, fatigue and global disease activity, height and weight. Body mass index (BMI) &lt;18.5 indicates UW, BMI 18.5-24.9 NW, BMI 25.0-29.9 OW and BMI ³30.0 OB. Results are presented as means with standard deviation (SD) or 95% confidence intervals (CI). <h3>Results</h3> Mean (SD) BMI in the RA population increased from 23.3(4.8) in 1994 to 25.1(4.6) in 2009. UW decreased from 6.3% to 3.7%, while OB increased from 5.1% to13.6% over the 15 years. Pain and disease activity levels were similar across BMI subgroups, with a trend towards higher values for UW and OB at all examination points with overlapping 95% CI. UW patients reported the worst physical function and lowest utility scores, and had highest age and longest disease duration. Age and disease duration for the entire population were not statistically different between examination points. NW were the youngest and had the highest utility SF6D score. OB had the shortest disease duration and MHAQ only improved from 04-09. SF-36 PCS scores mimicked MHAQ scores but OB were worse than UW. Pain and fatigue VAS scores were highest for UW and OB, data not included. NW and OW scored almost identical on all measures (data not included). <h3>Image/graph:</h3> <h3>Conclusions</h3> Even though the proportion of UW RA patients decreased during the observation period and they reported improved utility, physical function and global disease activity, they never caught up with the improvement seen in NW and OW RA patients. The increasing proportion of OB patients is a worrying trend, especially when considering the additional burden of other health problems. <h3>Disclosure of Interest</h3> None Declared